Semaglutide, an FDA-approved GLP-1 receptor agonist, offers proven clinical efficacy with extensive safety data, while 5-Amino-1MQ, an experimental NNMT inhibitor, shows promise in preclinical studies but lacks human clinical trials for weight loss applications
Quick turn around, began feeling better after about 1 week
AOD-9604 Oral vs Injection: Routes and Evidence AOD-9604 has been studied through more than one route, but doses cannot be directly converted between oral, intravenous, topical, nasal, and subcutaneous forms
For more comprehensive approaches to abdominal fat, the visceral fat loss peptide guide covers multiple strategies